Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of IgPro10 (Intravenous Immunoglobulin, Privigen®) for the Treatment of Adults With Systemic Sclerosis

NCT04138485 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT04138485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04138485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of IgPro10 (Intravenous Immunoglobulin, Privigen®) for the Treatment of Adults With Systemic Sclerosis
Lead sponsor
CSL Behring
Phase
Phase 2
Overall status
Withdrawn
Start date
December 20, 2019
Completion date
September 16, 2020
Enrollment
0 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse cutaneous systemic sclerosis